137 related articles for article (PubMed ID: 15912821)
1. [Combining effectiveness and tolerance].
Krankenpfl J; 2005; 43(1-3):26-7. PubMed ID: 15912821
[No Abstract] [Full Text] [Related]
2. Aripiprazole: novelty, adherence and understatement.
Fear C
Int J Neuropsychopharmacol; 2005 Mar; 8(1):131. PubMed ID: 15469664
[No Abstract] [Full Text] [Related]
3. The patient with schizophrenia taking aripiprazole: case report.
Uzun S; Kozumplik O; Mimica N; Folnegović-Smalc V
Psychiatr Danub; 2005 Dec; 17(3-4):234-5. PubMed ID: 16392433
[No Abstract] [Full Text] [Related]
4. [Aripiprazole in the treatment of schizophrenia].
Bridler R
Praxis (Bern 1994); 2005 Jun; 94(23):975-7. PubMed ID: 16001540
[No Abstract] [Full Text] [Related]
5. ["Higher outcomes"--optimizing therapy of schizophrenia].
Rüther E
Krankenpfl J; 2004; 42(5-6):151. PubMed ID: 15527215
[No Abstract] [Full Text] [Related]
6. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics].
Steinert T
Psychiatr Prax; 2007 Jul; 34(5):255-7. PubMed ID: 17607643
[No Abstract] [Full Text] [Related]
7. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
8. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
Prescrire Int; 2009 Dec; 18(104):251. PubMed ID: 20025091
[No Abstract] [Full Text] [Related]
10. Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
Hung GC; Chen YY
Pharmacopsychiatry; 2007 Mar; 40(2):83-4. PubMed ID: 17447180
[No Abstract] [Full Text] [Related]
11. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Thomas P
Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole in treatment-refractory schizophrenia.
Hsu WY; Lee CI; Chiu NY; Kahn DA
J Psychiatr Pract; 2009 May; 15(3):221-6. PubMed ID: 19461396
[TBL] [Abstract][Full Text] [Related]
13. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole in schizophrenia: consensus guidelines.
Travis MJ; Burns T; Dursun S; Fahy T; Frangou S; Gray R; Haddad PM; Hunter R; Taylor DM; Young AH
Int J Clin Pract; 2005 Apr; 59(4):485-95. PubMed ID: 15853869
[TBL] [Abstract][Full Text] [Related]
15. [Compliance].
Vandel P
Encephale; 2007 Jun; 33 Pt 3():S399-401. PubMed ID: 19101359
[No Abstract] [Full Text] [Related]
16. [Expectation and development of atypical antipsychotic drugs].
Ther Umsch; 2004 Sep; 61(9):1 p preceding 539. PubMed ID: 15493111
[No Abstract] [Full Text] [Related]
17. Aripiprazole in chronic schizophrenia: experiences in daily practice.
Fernald DS; van Dellen RT; Hovens JE; Loonen AJ
Acta Psychiatr Scand; 2006 Oct; 114(4):294; author reply 294. PubMed ID: 16968370
[No Abstract] [Full Text] [Related]
18. Aripiprazole (Abilify) for schizophrenia.
Med Lett Drugs Ther; 2003 Feb; 45(1150):15-6. PubMed ID: 12592215
[No Abstract] [Full Text] [Related]
19. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
MMW Fortschr Med; 2002 May; Suppl 2():89. PubMed ID: 12070872
[No Abstract] [Full Text] [Related]
20. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Kim SH; Ivanova O; Abbasi FA; Lamendola CA; Reaven GM; Glick ID
J Clin Psychopharmacol; 2007 Aug; 27(4):365-8. PubMed ID: 17632220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
